"Company","Current Parent Company","Parent at the Time of the Penalty Announcement","Recap of Ownership Changes","City / Town","County","Nation / Region","Company Number","Penalty (in pounds)","Penalty Year","Penalty Date","Offence Group","Offence Type","Violation Description","Settlement Type","Case Number","Agency","HQ Country of Parent","Ownership Structure of Parent","Major Industry of Parent","Specific Industry of Parent","Parent company ISIN","Source of Data","Source Notes" "Alliance Pharmaceuticals Limited and Alliance Pharma plc","Alliance Pharma PLC","Alliance Pharma PLC","","","","","","7,900,000","2022","20220203","competition-related offences","price-fixing or anti-competitive practices","Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation.","","","Competition and Markets Authority","United Kingdom","publicly traded","pharmaceuticals","pharmaceuticals","GB0031030819","https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug",""